HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

HIV prevention is entering a new phase with the rise of innovative medications like the twice-yearly injectable lenacapavir.

Why a twice‑yearly injection might prove to be a good shot Lenacapavir is a first-in-class HIV drug that works by targeting ...

HIV drugs can prevent HTLV-1 transmission and disease in mice, paving the way for trials to fight this long-overlooked, ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

Many at-risk Americans either do not know about PrEP or don't have access. Here's why raising awareness is key to ending the ...

Around 10 million people globally live with the life-threatening virus HTLV-1, yet it remains a poorly understood disease ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for ...

The recommendation comes just weeks after the US Food and Drug Administration (FDA) approved the drug for use. Lenacapavir trials were conducted in Uganda and South Africa and demonstrated 100% ...